Introduction to Neonatal Respiratory Challenges
Neonatal respiratory disorders lower the likelihood of survival for neonates globally. One of these disorders is Bronchopulmonary Dysplasia (BPD). This is a devastating condition that leads to chronic lung issues for premature infants, usually given prolonged mechanical ventilation. This condition is a result of the disruption of normal alveolar development. As a result, it is accompanied by long-term respiratory issues and pulmonary hypertension. In addition to the financial burden of prolonged hospital stays and expensive medical interventions, the family of the child suffers greatly from the emotional burden as well. Currently, there is an extremely high demand for new therapies because the existing therapies only help manage the symptoms and do not help reverse the damage to the respiratory system. Currently, the only interventions that deal with the clinical gaps are the regenerative therapies, and of these, the Stem Cell-based therapies are some of the most promising. Shifting focus to the repair of the cellular systems using regenerative therapies, instead of the currently available therapies that focus on symptom management, is a hope-inspiring approach to the restoration of the cellular systems using UC-MSCs.
Intricate Pathological Mechanisms
The pathological mechanisms that lead to injury of the neonatal lungs are accompanied by pro-inflammatory cytokine storms due to barotrauma and respiratory distress. In the newly developed neonatal lungs, the presence of oxygen and barotrauma disturb normal inflammation and angiogenesis, driving Bronchopulmonary Dysplasia. Due to the combined effects of cytokine storms and fibroblast proliferation, the neonatal lungs develop massive scarring and extremely large, poorly functioning alveoli. The poor cellular communication and excessive fibrosis cause vascular dysfunction and pulmonary failure. To reverse the damage, the Stem Cell therapy needs to be regenerative and anti-inflammatory, precisely like UC-MSCs. The disrupted cellular microenvironment requires molecular signals to reactivate arrested developmental programs. Addressing the pathophysiology of Bronchopulmonary Dysplasia requires developmental biology combined with exact molecular targeting, a potential uniquely held by UC-MSCs Stem Cell interventions.
The Limitations of Current Approaches
The existing medical protocols mostly use supportive care to survive the early and critical phases of premature infants facing Bronchopulmonary Dysplasia. Physicians frequently deliver exogenous surfactants, systemic corticosteroids and bronchodilators, and provide oxygen, among other interventions. While these interventions have been shown to lower mortality, they all have significant shortcomings. Corticosteroids have a well-established association with negative effects, including growth effects and neurodevelopmental outcomes. While prolonged exposure to oxygen is paradoxically more damaging to the cellular injury, by exacerbating oxidative stress, and while all forms of mechanical ventilation inflict injury to the lung, and therefore, cyclic trauma and ineffective repairs, the current approaches have no potential to restore the already damaged lung tissues, including the alveolar and pulmonary vasculature and do not address the chronic deficiencies. There is an urgent need for novel interventions like UC-MSCs Stem Cell therapy to address the severe neonatal lung diseases.
The Therapeutic Mechanisms of UC-MSCs
Repairing damaged lung tissues may be achieved with umbilical cord derived mesenchymal Stem Cells (UC-MSCs). UC-MSCs may be the first biological agents to target the cytokine storm, the hallmark of Bronchopulmonary Dysplasia, due to their demonstrated immunomodulation. After their delivery, this Stem Cell population migrates to the injury and provides numerous growth factors to the local tissue. Their local stimulation may promote the progression of lung septation and alveolar development. In addition, paracrine signaling from UC-MSCs promotes the growth of new blood vessels (angiogenesis) to repair disrupted networks for more effective transport of oxygen in Bronchopulmonary Dysplasia patients. Compared to other interventions, this Stem Cell therapy actively breaks down (degrades) fibrotic tissues which eliminate the possibility of long-term scarring. The remarkable living nature of these cells surpasses the boundaries of all forms of care by actually restoring supportive structures. With these living therapies, physicians can finally treat the primary (root) pathophysiological processes of this condition creating an unparalleled positive effect (therapeutic effect). Regenerative researchers consider this particular Stem Cell type the most advanced for the first genuine lung reset and growth (pulmonary regeneration) in the field.
Figure 1: The Therapeutic Mechanisms of UC-MSCs compared with Limitations of Current Approaches
Future Medical Trends in Thailand
Thailand is becoming the leading regional center for advanced regenerative medicine research, particularly involving UC-MSCs for conditions like Bronchopulmonary Dysplasia. The country has world-class clinical research infrastructure and a highly skilled professional workforce capable of creating new advanced Stem Cell medical interventions for children (pediatric). Adding these cellular therapies as part of the standard of care in Thailand will target an important objective of public health and will help improve the outcomes of survival for premature infants. Thailand’s robust (biotechnology) industry is currently working on optimization of cultivation systems to make regenerative therapies safe and available. Regulatory environments that accelerate the initiation and execution of innovative medical research (clinical research) are already in place. Controlling manufacturing costs of advanced therapies will ensure the broadest access to regenerative medicine and cellular therapies in the Thai market and the regional market. Thailand will become the leading country in the world to use UC-MSCs for neonatal regenerative therapies.
Summary
Realizing the severity (extensiveness) of neonatal lung disease like Bronchopulmonary Dysplasia mandates novel therapies to be developed, and advanced medical (therapeutic) Stem Cell care using UC-MSCs is necessary to improve (overcome) the current state of symptom management. The use of UC-MSCs has the potential to change the way we understand and approach the Stem Cell treatment of Bronchopulmonary Dysplasia (BPD). While halting damaging inflammation, this approach also initiates complex Alveolar regeneration. BPD is a progressive condition in which the inflammation and injury cause the disease to worsen over time. The positive outcome of these therapies will most likely halt the progression of the disease and provide affected children with the ability to breathe normally and relieve them of their chronic respiratory challenges. The ongoing research in Thailand will provide affected children the ability to breathe normally and relieve them of their chronic respiratory challenges. The application of regenerative biotechnology along with other therapeutic biotechnologies and Stem Cell therapies is a pioneering breakthrough in infant respiratory therapy and chronic lung condition treatment.